| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2022 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | Director | Sell | 350,000 | $3.91 | $1,369,095.00 | -4.6% | -2.1% | -41.0% | |
| Aug 5, 2022 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 20,000 | $16.00 | $320,000.00 | -27.3% | -32.9% | -12.9% | |
| Aug 5, 2022 | ZTS Zoetis Inc. | Polzer Robert J59 | Executive Vice President | Sell | 1,120 | $171.77 | $192,382.51 | -36.6% | -24.7% | +2.5% | |
| Aug 4, 2022 | SUPN Supernus Pharmaceuticals, Inc. | Martin Tami Tillotson54 | Sr. V.p., Regulatory Affairs | Sell | 5,000 | $32.98 | $164,900.00 | -5.4% | +4.7% | -1.9% | |
| Aug 4, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 4,552 | $225.81 | $1,027,887.12 | -11.1% | +14.6% | +6.8% | |
| Aug 4, 2022 | PLSH Panacea Life Sciences Holdings, Inc. | Buttorff Leslie | CEO | Buy | 18,800 | $0.10 | $1,851.00 | +0.3% | - | - | |
| Aug 3, 2022 | PCRX Pacira Biosciences, Inc. | Winston Roy68 | Chief Medical Officer | Sell | 476 | $55.70 | $26,513.20 | -1.0% | -9.4% | -33.1% | |
| Aug 3, 2022 | PCRX Pacira Biosciences, Inc. | Slonin Jonathan72 | Chief Clinical Officer | Sell | 308 | $55.70 | $17,155.60 | -0.8% | -9.4% | -33.1% | |
| Aug 1, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $37.48 | $18,738.50 | -0.6% | -16.5% | +63.9% | |
| Aug 1, 2022 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 23,229 | $11.35 | $263,649.15 | -3.0% | -1.4% | +1.4% | |
| Jul 29, 2022 | TXMD Therapeuticsmd, Inc. | Rubric Capital Management LP | 10% Owner | Buy | 580,000 | $25.86 | $14,999,950.00 | +50.1% | -4.6% | -35.8% | |
| Jul 28, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 89,458 | $332.85 | $29,776,514.26 | - | +8.5% | +39.4% | |
| Jul 28, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 58,163 | $9.04 | $525,589.95 | -95.1% | -7.8% | -9.4% | |
| Jul 26, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 1,601 | $332.52 | $532,370.92 | - | +5.3% | +37.6% | |
| Jul 22, 2022 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 2,167 | $180.26 | $390,623.42 | -8.4% | -18.9% | +3.2% | |
| Jul 21, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $226.27 | $1,357,634.87 | -3.7% | -4.2% | +9.7% | |
| Jul 21, 2022 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 9,689 | $180.00 | $1,744,020.00 | -19.6% | -18.0% | +1.8% | |
| Jul 19, 2022 | ESPR Esperion Therapeutics, Inc. | Foody Joanne M.73 | Chief Medical Officer | Sell | 3,901 | $6.55 | $25,551.55 | -3.5% | +16.8% | -76.5% | |
| Jul 19, 2022 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 431 | $6.58 | $2,836.84 | -0.8% | +16.8% | -76.5% | |
| Jul 18, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | Director | Sell | 1,520 | $37.23 | $56,596.59 | -10.6% | -20.1% | +66.4% | |
| Jul 18, 2022 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,479 | $70.86 | $104,794.84 | -1.1% | +7.0% | +35.7% | |
| Jul 18, 2022 | TXMD Therapeuticsmd, Inc. | Rubric Capital Management LP | 10% Owner | Buy | 82,580 | $5.66 | $467,458.16 | +3.7% | +15.0% | -31.2% | |
| Jul 15, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | EVP Corp Admin Center | Sell | 10,837 | $36.64 | $397,083.01 | -7.7% | -22.5% | +51.0% | |
| Jul 15, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 17,310 | $332.76 | $5,760,012.90 | - | +0.5% | +36.4% | |
| Jul 11, 2022 | PCRX Pacira Biosciences, Inc. | Hastings Paul J77 | Director | Sell | 533 | $56.95 | $30,354.35 | -6.9% | -0.4% | -33.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.